Patient;Age;BMI;Stage;Treatment;Chemotherapy cycles;Maintenance;PARPi;Primary outcome;BRCA mutation;HRD
patient1;70;24,84098009;IVA;PDS;6.0;No;No;Partial Response;Yes;
patient2;61;27,14158239;IIIC;PDS;6.0;Bevacizumab;Yes;;;
patient3;67;33,12130679;IVB;NACT;6.0;No;No;Progressive Disease;;
patient4;70;27,60945176;IIIB;PDS;6.0;No;ND;Complete Response;;
patient5;57;19,94805977;IIIC;NACT;6.0;No;Yes;Partial Response;Yes;
patient6;72;24,64099896;IVB;NACT;6.0;No;Yes;;Yes;
patient7;40;31,64428577;IIIC;PDS;6.0;bevacizumab;No;Partial Response;;
patient8;57;21,45357371;IIB;NACT;6.0;No;Yes;Stable Disease;;HRD positive
patient9;83;24,38652644;IIIC;PDS;6.0;bevacizumab;No;Partial Response;;
patient10;68;22,77318641;IIIC;NACT;5.0;No;ND;ND;Yes;
patient11;80;27,62492564;IVA;NACT;6.0;bevacizumab;ND;Partial Response;;
patient12;75;23,7953599;IIIC;PDS;6.0;bevacizumab;No;Complete Response;;
patient13;59;19,6282647;;NACT;5.0;Bevacizumab +olaparib;No;Complete Response;;HRD negative
patient14;82;27,76709812;IIIC;PDS;7.0;No;No;Complete Response;;
patient15;73;23,62444749;IIIC;NACT;5.0;bevacizumab;ND;Partial Response;;
patient16;71;29,69104308;IVA;PDS;6.0;No;No;Stable Disease;Yes;
patient17;74;21,70792339;IVA;PDS;6.0;Placebo, Bevacizumab;ND;Complete Response;;
patient18;75;19,70553242;IVA;NACT;6.0;bevacizumab;No;Complete Response;;
patient19;63;28,71972318;IIIC;NACT;6.0;No;Yes;Partial Response;Yes;
patient20;59;25,46198063;IIIA1;NACT;7.0;Olaparib;Yes;Complete Response;;HRD positive
